logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN
HerediGENE

HerediGENE

HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are responsible for increased risk of developing breast, ovarian and other hereditary cancers.

Learn more
OncotypeDX<sup>®</sup><br /> Breast

OncotypeDX®
Breast

The OncotypeDX® breast cancer test is a diagnostic test created to help patients who have been recently diagnosed with early stage, estrogen receptor positive breast cancer.

Learn more
Com.Pl.i.t. DX<br/> Assay

Com.Pl.i.t. DX
Assay

Com.Pl.i.t. DX Assay is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.

Learn more
Mo.Re.

Mo.Re.

Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.

Learn more
cloud
cloud

Services

Molecular Genetics

Genekor is specialized in molecular genetics.

Utilizing cutting edge technology, our company offers all the validated molecular tools for the diagnosis, prognosis and individualized treatment.

cloud
cloud

Services

Oncology, Cardiology, Neurology and Pharmacogenetics

We focus on oncology, cardiology, neurology and pharmacogenomics. Our goal is to achieve the most direct, most valid and most economical diagnostic procedure in order to generally improve patient care.

Company

Genekor

GeneKor is multinational molecular diagnostics company founded in 2007 and operates molecular biology laboratories with state of the art equipment suitable to provide the highest quality of Molecular Services . We provide a diversification of services focused on improving patient care utilizing the latest technologies of prognostic, predictive, and personalized medicine.

The clinical expertise of GeneKor focuses on:

  • Response to Targeted Therapy
  • Pharmacogenetics
  • Determination of Hereditary Cancer (Breast Cancer , Colon Cancer , Thyroid Cancer , Pancreatic Cancer , etc.)
  • New Unique Technological Platforms (OncotypeDX BreastTM, OncotypeDX ColonTM, OncotypeDX ProstateTM, PCA3TM)

Genetic Predisposition to Male Breast Cancer: A Case Series

Angela Apessos, Konstantinos Agiannitopoulos, Georgia Pepe, Georgios N. Tsaousis, Panagiota Pitta, Chrysanthi Bili, Lina Florentin, Emmanouel Saloustros, Eleftherios Kampletsas, Dimitrios Tryfonopoulos, Nikolaos Tsoukalas, Evangelos Bournakis, Flora Zagouri, Athanassios Kotsakis, Anna Koumarianou, Ippokratis Korantzis, Ioannis Boukovinas, George Lypas, Georgios Fountzilas, Vasiliki Michalaki, Spyridon Xynogalos, Helena Linardou, Eirini Papadopoulou, George Nasioulas and Vassilis Georgoulias

Angela Apessos et al 2022

A novel deletion of exon 4 in the Ectodysplasin A gene associated with X-linked hypohidrotic ectodermal dysplasia

Konstantinos Agiannitopoulos, Georgios N. Tsaousis , Kevisa Potska , Eirini Papadopoulou , Anna Douka, George Nasioulas , Iphigenia Gintoni , Christos Yapijakis

Agiannitopoulos et al 2023

The evolution of comprehensive genetic analysis in neurology: Implications for precision medicine

Eirini Papadopoulou a,* , Georgia Pepe a , Spiridon Konitsiotis b , Maria Chondrogiorgi b , Nikolaos Grigoriadis c , Vasilios K. Kimiskidis d , Georgios Tsivgoulis e , Dimos D. Mitsikostasf , Elisabeth Chroni g , Eleni Domouzoglou h , Georgios Tsaousis a , Georgios Nasioulas a

Eirini Papadopoulou et al 2023
Change cookies consent Revoke cookies consent